Phase 0 Plus Expansion Study of AZD1390 in Recurrent GBM Patients
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center Phase 0/1b study that will enroll at least 14
participants with recurrent glioblastoma requiring re-radiation. The trial will be composed
of a Phase 0 component (subdivided into Arm A and Arm B), and an expansion Phase 1b. Patients
with tumors demonstrating a positive PK response in the Phase 0 component of the study will
graduate to an expansion phase that combines therapeutic dosing of AZD1390 plus
standard-of-care fractionated radiotherapy (RT).
Phase:
Early Phase 1
Details
Lead Sponsor:
Nader Sanai
Collaborators:
AstraZeneca Barrow Neurological Institute Ivy Brain Tumor Center